Issues related to drug pricing, including federal proposals impacting reimbursement, access, and affordability; Issues related to Medicare Drug negotiation and implementation of the Inflation Reduction Act; ORPHAN Cures Act and pharmacy benefit manager reform legislation (H.R. 1, One Big Beautiful Bill Act); Issues related to Most Favored Nation (MFN) pricing models
Literal federal measure citations: H.R. 1